Sign Up Today and Learn More About Watchmaker Genomics Stock
Invest in or calculate the value of your shares in Watchmaker Genomics or other pre-IPO companies through EquityZen's platform.
Watchmaker Genomics Stock (WATG)
Watchmaker Genomics is a biotechnology company that focuses on breakthrough applications for reading, writing, and editing DNA.
About Watchmaker Genomics Stock
Founded
2019
Headquarters
Boulder, CO, US
Industries
Software, Artificial Intelligence, Data and Analytics
Watchmaker Genomics Press Mentions
Stay in the know about the latest news on Watchmaker Genomics
Volta Labs and Watchmaker Genomics Partner to Introduce Callisto™ Complete Kit for DNA EF Library Prep at AGBT 2026
prnewswire • Feb 24, 2026
Volta Labs and Watchmaker Genomics Partner to Introduce Callisto™ Complete Kit for DNA EF Library Prep at AGBT 2026
biospace • Feb 23, 2026
Watchmaker Genomics Licenses CRISPR-Cas9 Technology From Caribou Biosciences
genomeweb • Feb 18, 2026
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample
pharmiweb • Feb 17, 2026
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample
businesswire • Feb 17, 2026
Watchmaker Genomics Management
Leadership team at Watchmaker Genomics
Board Member
Victor Tong
Board Observer
Justin Butler
Join now and verify your accreditation status to gain access to:
- Watchmaker Genomics Current Valuation
- Watchmaker Genomics Stock Price
- Watchmaker Genomics Management
- Available deals in Watchmaker Genomics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Watchmaker Genomics Cap Table and Funding History by Share Class and Liquidity Preferences
- Watchmaker Genomics Revenue and Financials
- Watchmaker Genomics Highlights
- Watchmaker Genomics Business Model
- Watchmaker Genomics Risk Factors
- Watchmaker Genomics Research Report from SACRA Research
Trading Watchmaker Genomics Stock
How to invest in Watchmaker Genomics stock?
Accredited investors can buy pre-IPO stock in companies like Watchmaker Genomics through EquityZen funds. These investments are made available by existing Watchmaker Genomics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Watchmaker Genomics stock?
Shareholders can sell their Watchmaker Genomics stock through EquityZen's private company marketplace. EquityZen's network includes over 430K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 51K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
